^
    Back
    Association details:
    Biomarker:CEACAM5 expression
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of SAR408701 in Patients With Advanced Solid Tumors

    Excerpt:
    ...Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy....
    Trial ID:
    CEACAM5
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

    Excerpt:
    ...- Expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) will be assessed centrally using the most recent archival tumor tissue (or, if...
    Trial ID:
    TusaRav-QT
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

    Published date:
    05/26/2022
    Excerpt:
    92 pts with heavily pretreated NSQ NSCLC and high (n = 64) or moderate (n = 28) CEACAM5 expression (≥ 2+ intensity in ≥ 50% of tumor cells or in ≥ 1% to < 50% of tumor cells, respectively) were treated with tusa...Of pts treated for ≥ 12 mo, PR occurred irrespective of CEACAM5 expression level….Almost half (47%) of pts who achieved a PR were treated for ≥ 1 y, suggesting that response to tusa in heavily pretreated pts was durable and frequently sustained.
    DOI:
    10.1200/JCO.2022.40.16_suppl.9039
    Trial ID:
    CEACAM5